These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
421 related articles for article (PubMed ID: 33744207)
1. Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y Pereira NL; Rihal C; Lennon R; Marcus G; Shrivastava S; Bell MR; So D; Geller N; Goodman SG; Hasan A; Lerman A; Rosenberg Y; Bailey K; Murad MH; Farkouh ME JACC Cardiovasc Interv; 2021 Apr; 14(7):739-750. PubMed ID: 33744207 [TBL] [Abstract][Full Text] [Related]
2. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial. Pereira NL; Farkouh ME; So D; Lennon R; Geller N; Mathew V; Bell M; Bae JH; Jeong MH; Chavez I; Gordon P; Abbott JD; Cagin C; Baudhuin L; Fu YP; Goodman SG; Hasan A; Iturriaga E; Lerman A; Sidhu M; Tanguay JF; Wang L; Weinshilboum R; Welsh R; Rosenberg Y; Bailey K; Rihal C JAMA; 2020 Aug; 324(8):761-771. PubMed ID: 32840598 [TBL] [Abstract][Full Text] [Related]
3. Risk of major adverse cardiovascular events of Biswas M; Kali MSK; Biswas TK; Ibrahim B Platelets; 2021 Jul; 32(5):591-600. PubMed ID: 32664772 [TBL] [Abstract][Full Text] [Related]
4. Bedside testing of CYP2C19 gene for treatment of patients with PCI with antiplatelet therapy. Al-Rubaish AM; Al-Muhanna FA; Alshehri AM; Al-Mansori MA; Alali RA; Khalil RM; Al Faraidy KA; Cyrus C; Sulieman MM; Vatte C; Claassens DMF; Ten Berg JM; Asselbergs FW; Al-Ali AK BMC Cardiovasc Disord; 2020 Jun; 20(1):268. PubMed ID: 32493215 [TBL] [Abstract][Full Text] [Related]
5. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis. Jiang M; You JH Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429 [TBL] [Abstract][Full Text] [Related]
6. Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention. Johnson SG; Gruntowicz D; Chua T; Morlock RJ J Manag Care Spec Pharm; 2015 Jul; 21(7):552-7. PubMed ID: 26108379 [TBL] [Abstract][Full Text] [Related]
7. Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China. Zhong Z; Hou J; Zhang Q; Li B; Li C; Liu Z; Yang M; Zhong W; He X; Wu H; Zhong M; Zhao P Eur J Clin Pharmacol; 2018 Apr; 74(4):423-431. PubMed ID: 29243114 [TBL] [Abstract][Full Text] [Related]
8. Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel. Doll JA; Neely ML; Roe MT; Armstrong PW; White HD; Prabhakaran D; Winters KJ; Duvvuru S; Sundseth SS; Jakubowski JA; Gurbel PA; Bhatt DL; Ohman EM; Fox KAA; J Am Coll Cardiol; 2016 Mar; 67(8):936-947. PubMed ID: 26916483 [TBL] [Abstract][Full Text] [Related]
9. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis. Westman PC; Lipinski MJ; Torguson R; Waksman R Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137 [TBL] [Abstract][Full Text] [Related]
10. A Genotype-Guided Strategy for Oral P2Y Claassens DMF; Vos GJA; Bergmeijer TO; Hermanides RS; van 't Hof AWJ; van der Harst P; Barbato E; Morisco C; Tjon Joe Gin RM; Asselbergs FW; Mosterd A; Herrman JR; Dewilde WJM; Janssen PWA; Kelder JC; Postma MJ; de Boer A; Boersma C; Deneer VHM; Ten Berg JM N Engl J Med; 2019 Oct; 381(17):1621-1631. PubMed ID: 31479209 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of clopidogrel versus prasugrel and ticagrelor for coronary artery disease treatment in patients with CYP2C19 LoF alleles: a systemic review and meta-analysis. Yoon HY; Lee N; Seong JM; Gwak HS Br J Clin Pharmacol; 2020 Aug; 86(8):1489-1498. PubMed ID: 32320492 [TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics of P2Y Thomas CD; Williams AK; Lee CR; Cavallari LH Pharmacotherapy; 2023 Feb; 43(2):158-175. PubMed ID: 36588476 [TBL] [Abstract][Full Text] [Related]
14. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC; Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498 [TBL] [Abstract][Full Text] [Related]
15. A study on the impact of CYP2C19 genotype and platelet reactivity assay on patients undergoing PCI. Rath PC; Chidambaram S; Rath P; Dikshit B; Naik S; Sahoo PK; Das B; Mahalingam M; Khandrika L; Jain J Indian Heart J; 2015; 67(2):114-21. PubMed ID: 26071289 [TBL] [Abstract][Full Text] [Related]
16. Bedside testing of CYP2C19 vs. conventional clopidogrel treatment to guide antiplatelet therapy in ST-segment elevation myocardial infarction patients. Al-Rubaish AM; Al-Muhanna FA; Alshehri AM; Al-Mansori MA; Alali RA; Khalil RM; Al-Faraidy KA; Cyrus C; Sulieman MM; Vatte C; Loza BL; Claassens DMF; Asselbergs FW; Al-Ali AK Int J Cardiol; 2021 Nov; 343():15-20. PubMed ID: 34506827 [TBL] [Abstract][Full Text] [Related]
17. Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review. AlMukdad S; Elewa H; Al-Badriyeh D J Cardiovasc Pharmacol Ther; 2020 May; 25(3):201-211. PubMed ID: 32027168 [TBL] [Abstract][Full Text] [Related]
18. Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis. Zhang L; Yang J; Zhu X; Wang X; Peng L; Li X; Cheng P; Yin T Thromb Res; 2015 Mar; 135(3):449-58. PubMed ID: 25511576 [TBL] [Abstract][Full Text] [Related]
19. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Mega JL; Close SL; Wiviott SD; Shen L; Walker JR; Simon T; Antman EM; Braunwald E; Sabatine MS Lancet; 2010 Oct; 376(9749):1312-9. PubMed ID: 20801494 [TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial. Sardella G; Calcagno S; Mancone M; Palmirotta R; Lucisano L; Canali E; Stio RE; Pennacchi M; Di Roma A; Benedetti G; Guadagni F; Biondi-Zoccai G; Fedele F Circ Cardiovasc Interv; 2012 Oct; 5(5):698-704. PubMed ID: 23048056 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]